A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis‐Related Arthritis

• Published in: Arthritis care & research (2010) Vol. 67; no. 11; pp. 1503 - 1512
• Main Authors: Burgos‐Vargas, Rubén, Tse, Shirley M. L., Horneff, Gerd, Pangan, Aileen L., Kalabic, Jasmina, Goss, Sandra, Unnebrink, Kristina, Anderson, Jaclyn K.
• Format: Journal Article
• Language: English
• Published: United States John Wiley and Sons Inc 01.11.2015
• Subjects: Adalimumab - therapeutic use; Adolescent; Antirheumatic Agents - therapeutic use; Arthritis, Juvenile - diagnosis; Arthritis, Juvenile - drug therapy; Child; Double-Blind Method; Female; Humans; Male; Pediatric Rheumatology; Treatment Outcome
• ISSN: 2151-464X; 2151-4658
• DOI: 10.1002/acr.22657

Objective Enthesitis‐related arthritis (ERA) is a juvenile idiopathic arthritis (JIA) category, primarily affecting entheses and peripheral joints. This study evaluated efficacy, safety, and pharmacokinetics of adalimumab versus placebo in patients with ERA. Methods This is a phase III, multicenter, randomized double‐blind study in patients ages ≥6 to <18 years with ERA treated with adalimumab (24 mg/m2, maximum dose 40 mg every other week) or placebo for 12 weeks, followed by up to 192 weeks of open‐label adalimumab. The primary end point was percent change from baseline in number of active joints with arthritis (AJC) at week 12. Samples were collected to determine adalimumab serum concentrations. Adverse events (AEs) were assessed throughout the study. Results Forty‐six patients were randomized (31 adalimumab/15 placebo). At baseline, mean age was 12.9 years, mean duration of ERA symptoms was 2.6 years, mean AJC was 7.8, and mean enthesitis count was 8.1. Mean percent change from baseline in AJC at week 12 was greater in the adalimumab group versus placebo (−62.6% versus −11.6%; P = 0.039). Most secondary variables favored adalimumab versus placebo at week 12. Treatment response further increased with continued adalimumab therapy through week 52. Mean steady‐state adalimumab serum concentrations were 7.5–11.8 μg/ml, similar to patients age ≥2 years with polyarticular JIA. AE rates were similar between placebo and adalimumab: any AE (53.3% versus 67.7%), serious AEs (0% versus 3.2%), and infectious AEs (20.0% versus 29.0%). Conclusion Adalimumab reduced signs and symptoms of ERA at week 12, with improvement sustained through week 52. The safety profile was consistent with previous adalimumab studies.